- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Management of myelofibrosis after ruxolitinib failure ; volume:99 ; number:6 ; day:20 ; month:3 ; year:2020 ; pages:1177-1191 ; date:6.2020
Annals of hematology ; 99, Heft 6 (20.3.2020), 1177-1191, 6.2020
- Urheber
-
Harrison, Claire N.
Schaap, Nicolaas
Mesa, Ruben A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-020-04002-9
- URN
-
urn:nbn:de:101:1-2020072319190810500694
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Harrison, Claire N.
- Schaap, Nicolaas
- Mesa, Ruben A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes